Company Description
Fortrea Holdings Inc., a contract research organization, primarily engages in the provision of biopharmaceutical product and medical device development services worldwide.
The company operates through two segments: Clinical Services and Enabling Services. The Clinical Services segment provides across the clinical pharmacology and clinical development spectrum.
The Enabling Services segment provides patient access and clinical trial technology solutions to customers that streamline complex randomization and optimize the trial drug supply process.
The company offers delivery models that include full service, functional service provider, and hybrid service structures.
It also offers phase I-IV clinical trial management, differentiated technology enabled trial solutions, and post approval services, as well as consulting services.
The company serves pharmaceutical, biotechnology, and medical device organizations. Fortrea Holdings Inc. was incorporated in 2023 and is headquartered in Durham, North Carolina.
| Country | United States |
| Founded | 1996 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 18,000 |
| CEO | Thomas Pike |
Contact Details
Address: 8 Moore Drive Durham, North Carolina 27709 United States | |
| Phone | 877 495 0816 |
| Website | fortrea.com |
Stock Details
| Ticker Symbol | FTRE |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001965040 |
| CUSIP Number | 34965K107 |
| ISIN Number | US34965K1079 |
| Employer ID | 92-2796441 |
| SIC Code | 8071 |
Key Executives
| Name | Position |
|---|---|
| Thomas H. Pike | Chief Executive Officer, President and Chairman |
| Jill McConnell | Chief Financial Officer |
| Mark A. Morais | Chief Operating Officer and President of Clinical Services |
| Robert Parks | Chief Accounting Officer |
| Hima B. Inguva | Head of Investor Relations and Corporate Development |
| Stillman Hanson | General Counsel and Corporate Secretary |
| Dr. John J. Doyle | President of Consulting |
| Amanda M. Warren | Advisor to the Chief Financial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 26, 2024 | 8-K/A | [Amend] Current report |
| Aug 12, 2024 | 10-Q | Quarterly Report |
| Aug 12, 2024 | 8-K | Current Report |
| Jul 11, 2024 | 8-K | Current Report |
| Jun 20, 2024 | 8-K | Current Report |
| Jun 7, 2024 | 8-K/A | [Amend] Current report |
| Jun 4, 2024 | 8-K | Current Report |
| May 28, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| May 24, 2024 | 8-K | Current Report |
| May 24, 2024 | 10-Q | Quarterly Report |